Intera 3000™ Hepatic Artery Infusion Pump

Name: Intera 3000™ HAI Pump – Boston Scientific
Brand: Boston Scientific

The Intera 3000 HAI Pump is an FDA-approved, implantable pump used to treat tumors in the liver from colorectal cancer liver metastases (CRLM) and intrahepatic cholangiocarcinoma (iCCA).

Reimbursement

Reimbursement information

Coding and payment guides

Configure or select a product to continue to order

Access product literature

Instructions for use are found inside the product packaging and on our product literature website.

Overview
Technical and ordering information
Resources

A powerful liver-directed treatment for patients with CRLM and iCCA

HAI therapy exposes tumors in the liver to up to 400x greater drug concentration than systemic infusion while minimizing systemic exposure.¹

The HAI pump continuously perfuses the entire liver, allowing patients to maintain their quality of life.²

1. Ensminger WD, Gyves JW. Semin Oncol. 1983;10(2):176-8
2. Ensminger WD, et al. Cancer Res. 1978;38(11 Pt 1):3784-92.

Ordering information

Product Number	Material Description	Unit of Measure
AP03000H	INTERA 3000 HEPATIC ARTERY INFUSION PUMP	Each
IP37957	SILICONE TAPERED CATHETER	Each
AP040135	SPECIAL BOLUS NEEDLE 1-3/8"	Box of 5
AP040325	SPECIAL BOLUS NEEDLE, 2"	Box of 5
AP07014US	MODEL 3000 REFILL KIT US	Each
AP04030	NON-CORING REFILL NEEDLES 22g 2"	Box of 15

Clinical summary series:

HAI Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy

Taken together, results of the prospective phase II study and retrospective analysis of routine clinical care underscore the ability of HAI to achieve durable long-term disease control and prolonged survival in patients with advanced, unresectable iCCA.

Read the the full clinical summary

Clincal trial by Cowzer et al article summary.

Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma—PUMP-2 trial

A multicenter trial from the Netherlands—the PUMP-2 study—has shown remarkable survival benefits for patients with unresectable intrahepatic cholangiocarcinoma (iCCA) confined to the liver.